| 영문 | hormone | 한글 | 호르몬 |
|---|---|---|---|
| 설명 | 호르몬이란 특정한 내분비선에서 생성, 저장되어 있다가, 관류하는 혈액 중으로 분비된 다음 혈액에 실려 멀리 떨어져 있는 표적세포(호르몬이 작용을 나타내는 세포)에 이르러 그곳에서 특정한 기능을 발휘하는 물질을 말한다. 내분비샘이 아니더라도 어느 세포나 세포군에서 세포외액 중으로 분비된 다음 다른 세포에 가서 세포의 기능을 변동시키는 물질의 일부도 호르몬의 범주에 포함시키고 있으며 이들을 특별히 국소호르몬이라 부른다(예-아세틸콜린, 아드레날린, 콜레시스토키닌 등). 이에 비해서 특정 내분비샘에서 혈중으로 분비되는 진정한 의미의 호르몬들을 일반호르몬이라고 부른다. 호르몬을 흔히 3종의 무리로 분류를 하는데 아드레날린이나 thyroxine과 같이 아미노산의 유도체로 된 호르몬들(amine derivative), 많은 아미노산을 재료로 만들어졌거나 당단백으로 된 단백호르몬(peptide hormone), 그리고 콜레스테롤을 재료로 만들어진 지방호르몬(steroid hormone) 등으로 구분되며 이들은 대체로 종류에 따라 작용메커니즘을 달리하고 있다. |
||
| 영문 | luteinizing hormone(LH) | 한글 | 황체형성호르몬 |
|---|---|---|---|
| 설명 | 여성의 월경은 정해진 순서에 의해 일어나게 된다. 먼저 난포자극호르몬이 뇌에서 분비되어 여성의 난소를 자극하게 되면 난포가 자극받아 난포호르몬(에스트로젠)을 분비하게 되고 이것은 다시 되먹이기 메커니즘 의해 뇌에 작용을 하여 황체화호르몬이 뇌에서 분비되고 이것이 이른바 절정에 이르렀을 때, 난포에서 배란이 일어나게 된다. 이후 난포는 황체로 변하게 되며, 배란된 난자가 수정되지 아니하면, 황체는 황체호르몬(프로게스테론)을 분비한 뒤 퇴화되고 곧 이어 월경이 일어나게 된다. 이 일은 정상적인 대부분의 여성에서 28일을 주기로 일어나며, 대개 황체화호르몬 절정 이후 마지막은 14일로 일정하다고 한다. |
||
| AL | absolute latency; acinar lumen; acute leukemia; adaptation level; albumin; alcoholism [and other dru... |
|---|---|
| AMSAODD | American Medical Society on Alcoholism and Other Drug Dependencies |
| AODP | alcohol and other drug problems |
| Nutcracker syndrome | the vein from the left kidney is obstructed by one of the major arteries leaving the aorta. It can c... |
| ABC | absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a... |
| androgen antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of androgens. (12 Dec 1998) |
|---|---|
| gaba antagonists | Drugs that bind to but do not activate gaba receptors, thereby blocking the actions of endogenous gaba or gaba agonists. (12 Dec 1998) |
| cholinergic antagonists | Drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. (12 Dec 1998) |
| muscarinic antagonists | Drugs that bind to but do not activate muscarinic cholinergic receptors (receptors, muscarinic), thereby blocking the actions of endogenous acetycholine or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antagonists that discriminate among the various muscarinic receptor subtypes and might allow better control of peripheral and central actions are under development. (12 Dec 1998) |
| heparin antagonists | Coagulant substances inhibiting the anticoagulant action of heparin. (12 Dec 1998) |
| prostaglandin antagonists | Compounds that inhibit the action of prostaglandins. (12 Dec 1998) |
| histamine antagonists | Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonist. Classical antihistaminics block the histamine h1 receptors only. (12 Dec 1998) |
| histamine h1 antagonists | Drugs that selectively bind to but do not activate histamine h1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonise or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system h1 receptors are not as well understood. (12 Dec 1998) |
| histamine h2 antagonists | Drugs that selectively bind to but do not activate histamine h2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. (12 Dec 1998) |
| serotonin antagonists | Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonin agonists. (12 Dec 1998) |
| narcotic antagonists | Agents inhibiting the effect of narcotics on the central nervous system. (12 Dec 1998) |
| nicotinic antagonists | Drugs that bind to nicotinic cholinergic receptors (receptors, nicotinic) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (12 Dec 1998) |
| dopamine antagonists | Drugs that bind to but do not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (antipsychotic agents) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as antiemetics, in the treatment of tourette syndrome, and for hiccup. (12 Dec 1998) |
| opioid antagonists | Agents such as naloxone and naltrexone which have high affinity for opiate receptors but do not activate these receptors. These drugs block the effects of exogenously administered opioids such as morphine, heroin, meperidine, and methadone, or of endogenously released endorphins and enkephalins. (05 Mar 2000) |
| estradiol antagonists | Compounds which inhibit or antagonise the biosynthesis or action of estradiol. (12 Dec 1998) |